RESEARCH-USE BIOSIMILAR ANTIBODY
Satralizumab
Monoclonal antibody · IgG2
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
TARGETChugai Pharmaceutical
YMonoclonal antibody
TARGETRoche
CATALOG NUMBERSC-BS-187
MOLECULAR WEIGHTApprox. 144.5 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
Satralizumab is a recombinant research-use antibody directed against Chugai Pharmaceutical / Roche.